CD59 incorporation protects hepatitis C virus against complement-mediated destruction

Hepatology

Volumn 55, Issue 2, 2012, Pages 354-363

  Amet, Tohti ^a   Ghabril, Marwan ^a   Chalasani, Naga ^a   Byrd, Daniel ^a   Hu, Ningjie ^a   Grantham, Ayslinn ^a   Liu, Ziqing ^a   Qin, Xuebin ^b   He, Johnny J ^a   Yu, Qigui ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIC 229; CD59 ANTIGEN; COMPLEMENT; MONOCLONAL ANTIBODY; RECOMBINANT INTERMEDILYSIN DOMAIN 4 PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS INFECTION; ADULT; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL; MALE; PRIORITY JOURNAL; SUPERNATANT; VIRION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS PURIFICATION;

ANTIGENS, CD59; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNITY, HUMORAL; MALE; MIDDLE AGED; VIRION;

EID: 84856247041     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24686     Document Type: Article

References (21)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
2. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995; 182: 501-509.
3. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000; 74: 3264-3272.
4. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 1998; 95: 7544-7549.
5. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995; 155: 4376-4381.
6. Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 2010; 184: 359-368.
7. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262: 5-25.
8. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bögel M, Gigli I, et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 1995; 96: 1520-1526.
9. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003; 100: 14199-14204.
10. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 2005; 41: 667-675.
11. Merz A, Long G, Hiet MS, Brügger B, Chlanda P, Andre P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011; 286: 3018-3032.
12. Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010; 84: 10999-11009.
13. Fukasawa M. Cellular lipid droplets and hepatitis C virus life cycle. Biol Pharm Bull 2010; 33: 355-359.
14. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 2005; 1: 333-337.
15. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10: 821-827.
16. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. HEPATOLOGY 2004; 39: 5-19.
17. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
18. Bonnon C, Wendeler MW, Paccaud JP, Hauri HP. Selective export of human GPI-anchored proteins from the endoplasmic reticulum. J Cell Sci 2010; 123: 1705-1715.
19. Chuang WC, Allain JP. Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol 2008; 89: 1890-1900.
20. Ott DE. Cellular proteins detected in HIV-1. Rev Med Virol 2008; 18: 159-175.
21. Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 2010; 141: 799-811.